TSCAN THERAPEUTICS INC (TCRX) Stock Price & Overview
NASDAQ:TCRX • US89854M1018
Current stock price
The current stock price of TCRX is 1.06 USD. Today TCRX is up by 4.95%. In the past month the price decreased by -10.62%. In the past year, price decreased by -8.18%.
TCRX Key Statistics
- Market Cap
- 60.314M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.00
- Dividend Yield
- N/A
TCRX Stock Performance
TCRX Stock Chart
TCRX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TCRX. When comparing the yearly performance of all stocks, TCRX is a bad performer in the overall market: 74.32% of all stocks are doing better.
TCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TCRX. TCRX may be in some trouble as it scores bad on both profitability and health.
TCRX Earnings
On March 4, 2026 TCRX reported an EPS of -0.18 and a revenue of 2.57M. The company beat EPS expectations (26.83% surprise) and beat revenue expectations (22.88% surprise).
TCRX Forecast & Estimates
13 analysts have analysed TCRX and the average price target is 7.34 USD. This implies a price increase of 592.83% is expected in the next year compared to the current price of 1.06.
For the next year, analysts expect an EPS growth of 8.69% and a revenue growth -20.7% for TCRX
TCRX Groups
Sector & Classification
TCRX Financial Highlights
Over the last trailing twelve months TCRX reported a non-GAAP Earnings per Share(EPS) of -1. The EPS increased by 13.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.72% | ||
| ROE | -105.4% | ||
| Debt/Equity | 0.26 |
TCRX Ownership
TCRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.86 | 369.265B | ||
| AMGN | AMGEN INC | 14.98 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.79 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.24 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.29 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.55 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.58 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.43 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCRX
Company Profile
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 142 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Company Info
IPO: 2021-07-16
TSCAN THERAPEUTICS INC
830 Winter Street
Waltham MASSACHUSETTS US
CEO: David Southwell
Employees: 142
Phone: 18573999500
TSCAN THERAPEUTICS INC / TCRX FAQ
What does TSCAN THERAPEUTICS INC do?
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 142 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
What is the stock price of TSCAN THERAPEUTICS INC today?
The current stock price of TCRX is 1.06 USD. The price increased by 4.95% in the last trading session.
What is the dividend status of TSCAN THERAPEUTICS INC?
TCRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TCRX stock?
TCRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for TSCAN THERAPEUTICS INC?
The Revenue of TSCAN THERAPEUTICS INC (TCRX) is expected to decline by -20.7% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does TSCAN THERAPEUTICS INC have?
TSCAN THERAPEUTICS INC (TCRX) currently has 142 employees.